Molecular Analysis for Combination Therapy Choice (ComboMATCH) Protocol EAY191-A3, A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers (NCT05554367)
Primary Objective
To screen and assign patients to ComboMATCH treatment trials.

Description
To screen and assign patients to ComboMATCH treatment trials.
Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Visit ClinicalTrials.gov to learn more about this study.
Locations
Greeley Campus
Harmony Campus
Medical Center of the Rockies
Outpatient CTRC
Poudre Valley Hospital
University of Colorado Hospital
Principal Investigator

Robert Lentz
Study ID
Protocol Number: 24-0233
More information available at ClinicalTrials.gov: NCT05554367
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers